Detalhe da pesquisa
1.
Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trialâ.
Ann Oncol
; 31(10): 1350-1358, 2020 10.
Artigo
Inglês
| MEDLINE | ID: mdl-32634611
2.
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET).
Ann Oncol
; 27(9): 1719-25, 2016 09.
Artigo
Inglês
| MEDLINE | ID: mdl-27358383
3.
Complications of hyperglycaemia with PI3K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials.
Br J Cancer
; 113(11): 1541-7, 2015 Dec 01.
Artigo
Inglês
| MEDLINE | ID: mdl-26554652
4.
Reprint of 'Tracking the blue: a MLST approach to characterise the Pseudomonas fluorescens group'.
Food Microbiol
; 45(Pt A): 148-58, 2015 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-25481072
5.
Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional study.
Breast Cancer Res Treat
; 148(3): 511-23, 2014 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-25395316
6.
Tracking the blue: a MLST approach to characterise the Pseudomonas fluorescens group.
Food Microbiol
; 39: 116-26, 2014 May.
Artigo
Inglês
| MEDLINE | ID: mdl-24387861
7.
Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications.
Ann Oncol
; 24(11): 2715-24, 2013 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-23908178
8.
Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives.
Ann Oncol
; 24(7): 1740-1748, 2013 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-23585514
9.
Discontinuation rate and serious adverse events of chemoimmunotherapy as neoadjuvant treatment for triple-negative breast cancer: a systematic review and meta-analysis.
ESMO Open
; 8(6): 102198, 2023 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-38100933
10.
Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer.
Ann Oncol
; 23(6): 1436-41, 2012 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-22039084
11.
Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancer.
ESMO Open
; 7(5): 100561, 2022 10.
Artigo
Inglês
| MEDLINE | ID: mdl-36084395
12.
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).
ESMO Open
; 6(1): 100019, 2021 02.
Artigo
Inglês
| MEDLINE | ID: mdl-33399082
13.
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study.
ESMO Open
; 6(2): 100099, 2021 04.
Artigo
Inglês
| MEDLINE | ID: mdl-33819752
14.
How do novel and conventional agri-food wastes, co-products and by-products improve soil functions and soil quality?
Waste Manag
; 113: 132-144, 2020 Jul 15.
Artigo
Inglês
| MEDLINE | ID: mdl-32531661
15.
Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population.
Clin Transl Oncol
; 22(10): 1857-1866, 2020 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-32170637
16.
Simplified cell culture method for the diagnosis of atypical primary ciliary dyskinesia.
Thorax
; 64(12): 1077-81, 2009 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-19770168
17.
Oral etoposide in heavily pre-treated metastatic breast cancer: A retrospective series.
Breast
; 38: 160-164, 2018 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-29413403
18.
Patients with advanced stage breast carcinoma immunoreactive to biotinylated Herceptin are most likely to benefit from trastuzumab-based therapy: an hypothesis-generating study.
Ann Oncol
; 18(12): 1963-8, 2007 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-17785760
19.
Concurrent radiotherapy does not affect adjuvant CMF delivery but is associated with increased toxicity in women with early breast cancer.
J Chemother
; 18(1): 90-7, 2006 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-16572899
20.
HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation.
Clin Cancer Res
; 7(12): 4008-12, 2001 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-11751494